KR20160102965A - 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 - Google Patents
사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 Download PDFInfo
- Publication number
- KR20160102965A KR20160102965A KR1020167011298A KR20167011298A KR20160102965A KR 20160102965 A KR20160102965 A KR 20160102965A KR 1020167011298 A KR1020167011298 A KR 1020167011298A KR 20167011298 A KR20167011298 A KR 20167011298A KR 20160102965 A KR20160102965 A KR 20160102965A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- ucb
- subject
- cell
- placental perfusate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 469
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 27
- 210000002826 placenta Anatomy 0.000 title claims description 85
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 6
- 230000003169 placental effect Effects 0.000 claims abstract description 165
- 206010068051 Chimerism Diseases 0.000 claims abstract description 32
- 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 19
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 19
- 208000019838 Blood disease Diseases 0.000 claims abstract description 8
- 201000005787 hematologic cancer Diseases 0.000 claims abstract description 8
- 208000014951 hematologic disease Diseases 0.000 claims abstract description 8
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims abstract description 8
- 208000018706 hematopoietic system disease Diseases 0.000 claims abstract description 8
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 8
- 210000004700 fetal blood Anatomy 0.000 claims description 330
- 238000000034 method Methods 0.000 claims description 125
- 230000010412 perfusion Effects 0.000 claims description 79
- 239000012530 fluid Substances 0.000 claims description 50
- 210000005087 mononuclear cell Anatomy 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 238000002054 transplantation Methods 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 210000001185 bone marrow Anatomy 0.000 claims description 14
- 210000005259 peripheral blood Anatomy 0.000 claims description 14
- 239000011886 peripheral blood Substances 0.000 claims description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010058314 Dysplasia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 230000001919 adrenal effect Effects 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000005980 beta thalassemia Diseases 0.000 claims description 3
- 210000002449 bone cell Anatomy 0.000 claims description 3
- 230000005983 bone marrow dysfunction Effects 0.000 claims description 3
- 208000003669 immune deficiency disease Diseases 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims description 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 2
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims description 2
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims description 2
- 208000015872 Gaucher disease Diseases 0.000 claims description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 208000026589 Wolman disease Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229920000855 Fucoidan Polymers 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000000203 mixture Substances 0.000 abstract description 13
- 210000001616 monocyte Anatomy 0.000 abstract description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 31
- 210000003954 umbilical cord Anatomy 0.000 description 18
- 230000037396 body weight Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 230000003750 conditioning effect Effects 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 11
- 230000036266 weeks of gestation Effects 0.000 description 10
- 238000002513 implantation Methods 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000003606 umbilical vein Anatomy 0.000 description 9
- 238000010257 thawing Methods 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 210000001644 umbilical artery Anatomy 0.000 description 6
- 108091092878 Microsatellite Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 208000035010 Term birth Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000004159 blood analysis Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 206010036595 Premature delivery Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 241000238097 Callinectes sapidus Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000013265 Syntaxin 1 Human genes 0.000 description 1
- 108010090618 Syntaxin 1 Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886648P | 2013-10-03 | 2013-10-03 | |
| US61/886,648 | 2013-10-03 | ||
| US201361890057P | 2013-10-11 | 2013-10-11 | |
| US61/890,057 | 2013-10-11 | ||
| PCT/US2014/058774 WO2015051088A1 (en) | 2013-10-03 | 2014-10-02 | Therapy with cells from human placenta and hematopoietic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217013395A Division KR20210054046A (ko) | 2013-10-03 | 2014-10-02 | 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160102965A true KR20160102965A (ko) | 2016-08-31 |
Family
ID=52779130
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167011298A Ceased KR20160102965A (ko) | 2013-10-03 | 2014-10-02 | 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 |
| KR1020227010134A Ceased KR20220044384A (ko) | 2013-10-03 | 2014-10-02 | 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 |
| KR1020217013395A Ceased KR20210054046A (ko) | 2013-10-03 | 2014-10-02 | 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227010134A Ceased KR20220044384A (ko) | 2013-10-03 | 2014-10-02 | 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 |
| KR1020217013395A Ceased KR20210054046A (ko) | 2013-10-03 | 2014-10-02 | 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179152B2 (enExample) |
| EP (1) | EP3052109B8 (enExample) |
| JP (4) | JP2016531889A (enExample) |
| KR (3) | KR20160102965A (enExample) |
| CN (1) | CN105792834A (enExample) |
| AU (3) | AU2014329513A1 (enExample) |
| CA (1) | CA2926199C (enExample) |
| DK (1) | DK3052109T3 (enExample) |
| MX (2) | MX2016004209A (enExample) |
| RU (2) | RU2016116816A (enExample) |
| WO (1) | WO2015051088A1 (enExample) |
| ZA (1) | ZA201602151B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10426796B2 (en) | 2016-06-13 | 2019-10-01 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| US10456423B2 (en) | 2016-06-13 | 2019-10-29 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437994A (en) * | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
| IL107483A0 (en) * | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| WO2002064755A2 (en) * | 2001-02-14 | 2002-08-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| BRPI0407427A (pt) * | 2003-02-13 | 2006-01-24 | Anthrogenesis Corp | Método para tratar um paciente e para tratar a mielodisplasia |
| WO2007079184A2 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| EP1987135A2 (en) * | 2006-01-27 | 2008-11-05 | Auxocell Laboratories, Inc. | Methods and compositions relating to stem cell transplantation |
| JP5260499B2 (ja) * | 2006-05-11 | 2013-08-14 | コード ブラッド サイエンス インコーポレイテッド | 臍帯血幹細胞の回収方法及び使用方法 |
| US8263065B2 (en) * | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
-
2014
- 2014-10-02 WO PCT/US2014/058774 patent/WO2015051088A1/en not_active Ceased
- 2014-10-02 RU RU2016116816A patent/RU2016116816A/ru unknown
- 2014-10-02 RU RU2019131152A patent/RU2019131152A/ru unknown
- 2014-10-02 AU AU2014329513A patent/AU2014329513A1/en not_active Abandoned
- 2014-10-02 MX MX2016004209A patent/MX2016004209A/es unknown
- 2014-10-02 KR KR1020167011298A patent/KR20160102965A/ko not_active Ceased
- 2014-10-02 CA CA2926199A patent/CA2926199C/en active Active
- 2014-10-02 DK DK14850630.6T patent/DK3052109T3/da active
- 2014-10-02 JP JP2016519848A patent/JP2016531889A/ja active Pending
- 2014-10-02 KR KR1020227010134A patent/KR20220044384A/ko not_active Ceased
- 2014-10-02 KR KR1020217013395A patent/KR20210054046A/ko not_active Ceased
- 2014-10-02 US US15/026,896 patent/US10179152B2/en active Active
- 2014-10-02 CN CN201480066174.6A patent/CN105792834A/zh active Pending
- 2014-10-02 EP EP14850630.6A patent/EP3052109B8/en active Active
-
2016
- 2016-03-31 ZA ZA2016/02151A patent/ZA201602151B/en unknown
- 2016-04-01 MX MX2021003798A patent/MX2021003798A/es unknown
-
2019
- 2019-06-18 JP JP2019112450A patent/JP2019194211A/ja not_active Withdrawn
-
2020
- 2020-03-23 AU AU2020202076A patent/AU2020202076A1/en not_active Abandoned
-
2021
- 2021-04-07 JP JP2021065060A patent/JP2021107407A/ja not_active Withdrawn
-
2022
- 2022-08-10 AU AU2022215207A patent/AU2022215207A1/en not_active Abandoned
-
2023
- 2023-02-27 JP JP2023027978A patent/JP2023078156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016116816A (ru) | 2017-11-13 |
| KR20220044384A (ko) | 2022-04-07 |
| EP3052109B8 (en) | 2021-06-23 |
| AU2022215207A1 (en) | 2022-09-01 |
| KR20210054046A (ko) | 2021-05-12 |
| RU2019131152A3 (enExample) | 2022-02-24 |
| MX2021003798A (es) | 2021-05-27 |
| NZ718571A (en) | 2023-12-22 |
| AU2014329513A1 (en) | 2016-04-28 |
| EP3052109B1 (en) | 2021-05-12 |
| JP2023078156A (ja) | 2023-06-06 |
| JP2021107407A (ja) | 2021-07-29 |
| RU2019131152A (ru) | 2019-11-11 |
| WO2015051088A1 (en) | 2015-04-09 |
| US20160235790A1 (en) | 2016-08-18 |
| CA2926199C (en) | 2022-05-17 |
| DK3052109T3 (da) | 2021-08-16 |
| CN105792834A (zh) | 2016-07-20 |
| MX2016004209A (es) | 2016-07-11 |
| ZA201602151B (en) | 2022-12-21 |
| JP2016531889A (ja) | 2016-10-13 |
| CA2926199A1 (en) | 2015-04-09 |
| US10179152B2 (en) | 2019-01-15 |
| JP2019194211A (ja) | 2019-11-07 |
| EP3052109A1 (en) | 2016-08-10 |
| AU2020202076A1 (en) | 2020-04-09 |
| RU2016116816A3 (enExample) | 2018-08-02 |
| EP3052109A4 (en) | 2017-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190004832A (ko) | 조산 합병증의 치료에 있어서의 제대혈의 용도 | |
| JP2023078156A (ja) | ヒト胎盤および造血細胞由来の細胞による治療 | |
| Surbek et al. | Can cord blood be used for autologous transfusion in preterm neonates? | |
| WO2019084546A1 (en) | INCREASE IN FERTILITY BY PLASMA RICH IN PLATELETS | |
| HK1227309B (en) | Therapy with cells from human placenta and hematopoietic cells | |
| HK1227309A1 (en) | Therapy with cells from human placenta and hematopoietic cells | |
| JP7744897B2 (ja) | 心臓血管疾患の治療 | |
| EP2089041A2 (en) | Methods for using aldhbr cells to supplement stem cell transplantation | |
| RU2590688C2 (ru) | Способ получения суспензии ядросодержащих клеток из пуповинной крови со стандартизированной концентрацией | |
| Royo et al. | Prenatal Diagnosis and Early Treatment of Immunodeficiencies in Man | |
| MYELOMA | Blood and Marrow Stem Cell Transplantation | |
| WO2023275880A1 (en) | Method of obtaining hsc population, t cell population and nk cell population and compositions thereof | |
| Andritsos et al. | Collection, processing, and infusion of adult hematopoietic stem cells (bone marrow and peripheral blood stem cells) | |
| Sesok-Pizzini | Intrauterine Transfusions | |
| Andritsos et al. | 27 Collection, Processing, and Infusion of Adult Hematopoietic Stem Cells (Bone | |
| HK40005831A (en) | Expansion and use of expanded nk cell fractions | |
| Talaulicar | Systemic aortoarteritis: a case review | |
| Roback et al. | HPC Products | |
| Yasmin et al. | Umbilical Cord Blood Saving-A Lifeline for a Lifetime | |
| HK1124484B (en) | Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use | |
| HK1124484A1 (en) | Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160428 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190930 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201103 Patent event code: PE09021S01D |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20210503 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210510 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20201103 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |